Akari Therapeutics (AKTX) Change in Cash (2014 - 2026)

Akari Therapeutics (AKTX) has 9 years of Change in Cash data on file, last reported at -$2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 14223.53% year-over-year to -$2.4 million; the trailing twelve-month figure through Mar 2026 stood at $186000.0 (down 86.04% YoY), and the FY2025 full-year result was $2.6 million, up 319.56% from the prior year.
• Change in Cash slipped to -$2.4 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $2.9 million in Q2 2024 to a low of -$4.4 million in Q2 2023.
• A 4-year average of -$801692.3 and a median of -$886000.0 in 2023 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash soared 558.35% in 2025 and plunged 14223.53% in 2026, its largest moves.
• Tracing AKTX's Change in Cash over 4 years: stood at -$886000.0 in 2023, then jumped by 146.61% to $413000.0 in 2024, then soared by 558.35% to $2.7 million in 2025, then tumbled by 189.55% to -$2.4 million in 2026.
• Business Quant data shows AKTX's Change in Cash at -$2.4 million in Q1 2026, $2.7 million in Q4 2025, and -$227000.0 in Q3 2025.